Investment Thesis
Aspire Biopharma is in severe financial distress with negative stockholders' equity of -$11.5M, indicating liabilities exceed assets and the company is technically insolvent. Operating losses of -$17.5M on minimal revenue of $1.9K demonstrate the company is pre-revenue with unsustainable cash burn of -$4.0M annually, consuming its limited cash reserves of $1.9M within months at current burn rates.
Strengths
- Gross margin of 45.5% on limited product sales suggests potential unit economics if revenue scales
- Maintains $1.9M in cash providing short-term runway
- Healthcare/biotech sector has potential for significant upside if clinical/regulatory milestones achieved
Risks
- Negative stockholders' equity of -$11.5M indicates technical insolvency and high bankruptcy risk
- Current ratio of 0.17x shows severe liquidity crisis with liabilities 5.8x current assets
- Operating cash flow of -$4.0M annual burn rate with only $1.9M cash means 5-6 months of runway remaining
- Negligible revenue of $1.9K indicates company has not achieved commercial traction
- Operating margin of -901,693% reflects massive losses relative to minimal sales base
- No insider purchases in 90 days suggests lack of confidence from management
Key Metrics to Watch
- Cash position and monthly burn rate - critical for survival timeline
- Revenue growth and path to positive unit economics - essential for viability
- Financing activity and debt restructuring announcements - likely necessity for continuation
- Clinical trial progress and regulatory milestones - only potential value driver
- Stockholders' equity trajectory - key indicator of solvency status
Financial Metrics
Revenue
1.9K
Net Income
-19.8M
EPS (Diluted)
$-0.43
Free Cash Flow
-4.0M
Total Assets
2.4M
Cash
1.9M
Profitability Ratios
Gross Margin
45.5%
Operating Margin
-901,693.3%
Net Margin
-1,018,707.6%
ROE
N/A
ROA
-822.8%
FCF Margin
-205,855.1%
Balance Sheet & Liquidity
Current Ratio
0.17x
Quick Ratio
0.17x
Debt/Equity
N/A
Debt/Assets
577.2%
Interest Coverage
-21.40x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T05:18:12.274145 |
Data as of: 2025-09-30 |
Powered by Claude AI